#8 Chiron
4560 Horton St.
Emeryville, CA 94608-2916
Tel: (510) 655-8730
Fax: (510) 655-9910
www.chiron.com
| Headcount |
5,400 |
|
| Year Established |
1981 |
|
| Biopharma Revenues |
$1,138 |
+15% |
| Total Revenues |
$1,920 |
+11% |
| Royalty Revenues |
$317 |
+9% |
| Net Income |
$187 |
+137% |
| R&D Budget |
$434 |
+1% |
| Drugs Approved/Launched |
| Drug |
Indication |
| cubicin (in EU) |
complicated skin and soft-tissue infections
|
Drugs Pending Approval
|
| Drug |
Indication |
pulminiq
|
lung-transplant immunosuppression
|
| Drugs in Phase IIb and Beyond |
| Drug |
Indication
|
tifacogin
|
severe community-acquired pneumonia
|
tobramycin
|
dry powder formulation |
| proleukin |
non-Hodgkin’s lymphoma |
| menACWY vaccine |
four meningococcal serogroups |
menB vaccine
|
meningococcus B
|
Early Research Projects
|
| Drug |
Indication |
chir-258
|
oncology
|
| chir-12.12 |
B-cell hematological tumors |
hcv vaccine
|
HCV |
Top Selling Drugs
|
| Drug |
Indication
|
Sales
|
(+/-%)
|
fluvirin
|
flu vaccine |
$97 |
n/a |
TOBI
|
antibiotic (cystic fibrosis) |
$232 |
+9% |
| betaseron* |
multiple sclerosis |
$142 |
+8% |
| proleukin |
cancer |
$124 |
-4% |
* sold wholesale to Berlex Laboratories/Schering AG
|
Account for 52% of total biopharma sales, up from 48% in 2004.
|
